Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.35 |
| ▸ | FNTB | P49356 | 4/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | BLVRB | P30043 | 1/20 | 0.32 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | PPID | Q08752 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530081 | 0.94 | FNTA (0.37) | FNTAFNTBPGGT1BCYP11B2CYP11B1 | |
| SCHEMBL3528585 | 0.87 | PGGT1B (0.33) | FNTAFNTBPGGT1B | |
| SCHEMBL3533800 | 0.84 | XDH (0.34) | FNTAFNTBCYP11B2CYP11B1XDH | |
| SCHEMBL3532538 | 0.84 | FNTA (0.37) | FNTAFNTBPGGT1BXDHABCC4 | |
| SCHEMBL3526201 | 0.82 | PPARD (0.31) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3526029 | 0.82 | XDH (0.33) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3530910 | 0.81 | AR (0.35) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3529214 | 0.80 | DGAT1 (0.34) | — | |
| SCHEMBL3525684 | 0.80 | — | — | |
| SCHEMBL3527873 | 0.80 | PGGT1B (0.35) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931337-B1 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1931337-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | PPARD, PPARA, PPARG | FNTA 2633/4885FNTB 2812/4885PGGT1B 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.